uniQure N.V. 
QURE is a leading gene therapy biotech targeting rare diseases like Huntington’s and hemophilia.
🔹 Bullish setup forming above $14.50–$15.00
🔹 Price Target: $28.00–$29.00
📈 Catalyst: FDA alignment on its Huntington’s program (AMT-130) clears the path for a BLA submission in Q1 2026, significantly derisking the development.
✅ Early data from AMT-130 is promising, tracking well with clinical and biomarker endpoints — potential first-mover in disease-modifying therapies for Huntington’s.
🧠 Expanding platform: AMT-260 (epilepsy) delivered a 92% seizure reduction in initial patient, showcasing pipeline breadth across CNS disorders.
🧬 QURE offers exposure to the fast-growing gene therapy space with high long-term upside potential if clinical momentum continues.
#QURE #GeneTherapy #BiotechStocks #FDA #BreakoutSetup #LongSetup #RareDiseases #HuntingtonsDisease #Epilepsy #SmallCapStocks #GrowthStocks #Healthcare #BiotechInvesting #TechnicalAnalysis #StockWatchlist #Bullish
QURE is a leading gene therapy biotech targeting rare diseases like Huntington’s and hemophilia.🔹 Bullish setup forming above $14.50–$15.00
🔹 Price Target: $28.00–$29.00
📈 Catalyst: FDA alignment on its Huntington’s program (AMT-130) clears the path for a BLA submission in Q1 2026, significantly derisking the development.
✅ Early data from AMT-130 is promising, tracking well with clinical and biomarker endpoints — potential first-mover in disease-modifying therapies for Huntington’s.
🧠 Expanding platform: AMT-260 (epilepsy) delivered a 92% seizure reduction in initial patient, showcasing pipeline breadth across CNS disorders.
🧬 QURE offers exposure to the fast-growing gene therapy space with high long-term upside potential if clinical momentum continues.
#QURE #GeneTherapy #BiotechStocks #FDA #BreakoutSetup #LongSetup #RareDiseases #HuntingtonsDisease #Epilepsy #SmallCapStocks #GrowthStocks #Healthcare #BiotechInvesting #TechnicalAnalysis #StockWatchlist #Bullish
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.